Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …

Highlights•Dual bronchodilator therapy has clinical benefits in COPD.•Combining a LABA
with a LAMA synergistically relaxes medium and small airways.•In some approved …

Background Type 2 inflammatory diseases often coexist in patients. Dupilumab targets type
2 inflammation and has demonstrated treatment benefits in patients with atopic dermatitis …

Objectives The aim of this study was to assess the current evidence for long-acting β2-
agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) …

RSV infection of the lower respiratory tract in infants is the leading cause of pediatric
hospitalizations and second to malaria in causing infant deaths worldwide. RSV also causes …

Parasympathetic activity is increased in patients with chronic obstructive pulmonary disease
(COPD) and asthma and appears to be the major reversible component of airway …

Dual bronchodilation therapy is the cornerstone for the treatment of chronic obstructive
pulmonary disease (COPD)[1]. Combining a long-acting β2 adrenoceptor (β2-AR) agonist …

The long-acting β 2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed dose
combination (FDC) therapy represents the cornerstone for the treatment of chronic …

Introduction: Treatment recommendations are based on randomized controlled trials (RCTs).
However, only about 1 in 20 people meet the inclusion criteria for RCTs forming consensus …

COVID-19 is a biphasic infectious disease with no approved vaccine or pharmacotherapy.
The first drug that has shown promise in reducing COVID-19 mortality in severely-ill patients …